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Abstract 
 
Polypills have been proven to improve the patient compliance to multi-drug treatment. However it is 
still poorly understood when the drugs of a polypill formulation are manufactured as a mixture. The 
formations of co-amorphous mixtures are one of the possible results of blending multiple drugs in a 
single process. This project investigated the co-amorphous mixtures of two model drugs, felodipine 
and paracetamol prepared by melt-cool method. The rationale of the model drug selections is based on 
the high interaction potentials (hydrogen bonding) between the two drugs as both contain hydrogen 
donors and acceptor groups. Three molar ratios of the co-amorphous systems of paracetamol and 
felodipine (P-F) were prepared and their physical stabilities were studied using SEM, DSC, 
ATR-FTIR and PXRD. It was noted that there is no clear intermolecular interaction between 
felodipine and paracetamol was identified. Higher paracetamol content led to poorer physical stability 
of the co-amorphous system which also led to hindered release of paracetamol. The dissolution rates 
of felodipine from the co-amorphous systems showed no significant improvement in comparison to 
crystalline felodipine indicating the rapid recrystallization of felodipine during the dissolution process. 
However the linear nearly zero order release of paracetamol indicated the entrapment of paracetamol 
in the recrystallized felodipine lattice. This confirmed the formation of co-amorphous mixture without 
specific hydrogen bonding between the two species. Soluplus was used as the polymeric excipient 
with an attempt to further improve the physical stability of the co-amorphous systems. The stability of 
P-F 1:1 loaded Soluplus HME extrudates showed significant improvement than the co-amorphous 
sample. However no significant dissolution enhancement was observed. This could be partially 
attributed to the use of the extrudates in the rod form instead of power form in the dissolution tests. 
Controlled release of paracetamol and poor dissolution of felodipine were obtained from the HME 
samples indicating the poor solubility enhancement capability of Soluplus in this formulation. The 
results of this project provided further understanding of the behaviour of co-amorphous system which 
non-specific interactions.  
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Chapter 1 Introduction 
 
Background 
 
Polypills, such as Triveram (perindopril, amlodipine, and atorvastatin) from Servier, as approved 
products are used in more than 30 countries worldwide. Polypills are the medications that contain 
more than 1 pharmaceutical active ingredient. Clinical data has shown the improved patient adherence 
with using polypills for particular chronic diseases such as cardiovascular disease (CVD). The CVD 
polypills can be defined as combination medication containing at least one blood pressure-lowering 
and one lipid-lowering drug (Huffman et al., 2017). Several studies have found improvement in 
medication adherence with the polypill. For example, 2,004 patients with established CVD or 
calculated 5-year CVD risk >15% were randomized to a polypill or usual medical therapy in UMPIRE 
(Use of a Multidrug Pill In Reducing cardiovascular Events) the adherence was improved to 33% in 
the polypills cohort, accompanied by a significant reduction in systolic blood pressure and low-density 
lipoprotein (Liu et al., 2010). 
 
Many of the drugs in the polypills are poor water-soluble. In the recent years, the high throughput 
screening methods have led to more than 80% of the new chemical entities have poor aqueous 
solubility (Guo and Huang, 2014). By modifying chemical structure of the compound, the solubility of 
the compound can be improved. Formulation strategies such as reduction of particle size, formation of 
complexes, surface properties and solid dispersion technology have been widely used to improve the 
dissolution rate of the poorly soluble drugs (Guo and Huang, 2014).  
 
For polypills, depending on the physicochemical properties of the drugs, traditional processing 
methods such as granulation, tableting and hot melt extrusion (HME) techniques can be used for 
polypills formulation production. In the manufacturing process, often all APIs of the polypills are 
processed together. In processes such as HME which has been used widely for producing formulations 
of poorly soluble drugs, when all drugs are mixed and melted in the extruder, co-amorphous systems 
are likely to form. However the behaviour of co-amorphous systems are still not fully understood. 
Therefore this project is particularly dedicated to providing a fuller understanding of co-amorphous 
systems containing poorly soluble drugs and their physical stabilities.   
 
1.1 Co-amorphous materials 
1.1.1 Amorphous materials 
An amorphous material can be defined with the reference to its crystalline counterpart. The lattice 
structure of crystallization drugs can be broken (such as melting and dissolution) by inputting certain 
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amount of energy to overcome the intermolecular bonds. During such events, the molecular 
arrangement of the drug can be changed from ordered state to random state which is either a 
disordered state or the fully amorphous state. The more thermodynamically stable the lattice structure 
is, the more energy is required to disrupt or break the structure. Amorphous materials are 
thermodynamically instable with higher molecular mobility than their crystalline state. As it has been 
mentioned above that the physical stability of the co-amorphous system can be attributed to 
intermolecular interactions (e.g. H-bonding and/or π–π interactions). The changes in H-bonding or π-π 
interactions of functional groups are usually detectable via two main approaches such as: a 
Flory−Huggins interaction and quantum mechanical calculations. The Flory−Huggins interaction is 
good approach for predicting the physical stability of co-amorphous system. It relies on the 
thermodynamic and reaction kinetic factors for the modelling successful a stable co-amorphous 
system, the two factors govern transformational stages in experimental phases. The approach is 
usually used in the fast screening of the potential drug–drug combinations to produce a stable 
amorphous formulation. The second approach is based on the quantum mechanical calculations 
(Density functional theory (DFT)), where the calculations are based on fitted Coulomb integrals to 
reduce the computational time and generating accurate energy values. The DFT has been utilised in 
the pharmaceutical field and has revealed to be a valuable tool in predicting interactions in detail. 
Consequently, changing the state of drugs from crystallization state to amorphous state can 
significantly increase the dissolution rate as well as the physical instability (Bates et al., 2006). By 
changing the state of drugs from crystallization to amorphous state, the oral bioavailability of poorly 
water-soluble drugs can be improved greatly (Bates et al., 2006). There are two commonly reported 
methods to transform a crystalline material into its amorphous state, milling and super-cooling from 
melt/solvent evaporation (Hancock and Zografi, 1997).  
 
1.1.2 Definition of co-amorphous material 
The co-amorphous drug delivery systems have been widely investigated in pharmaceutical community 
as an alternative formulation strategy for delivery poorly soluble drugs. As illustrated in Figure 1.1, a 
co-amorphous system can be described as a multi-component single phase amorphous solid system 
which lacks periodicity in lattice and is associated by weak and discrete intermolecular interactions 
between the components (Suresh et al., 2014). There are two types of co-amorphous systems that have 
been reported recently, drug–drug combinations and drug–excipient mixtures (Löbmann, 2014). For 
drug-drug co-amorphous systems, two pharmacologically relevant drugs intended for multidrug 
therapies are combined, where one of drugs stabilize other one in the amorphous form. Both drugs act 
as an active component and stabilizing excipient at the same time (Swapnil et al., 2016). This is the 
type of co-amorphous drug system investigated in this project. In the second type, some small 
molecular weight excipients such as amino acids and carboxylic acids are used to prepare 
co-amorphous drug-excipient system with higher solubility (Rahul and Chavana, 2016). 
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Figure 1.1 Illustration of the molecular level structures of amorphous drug, crystalline drug and 
co-amorphous blend (Dengale et al., 2016) 
 
1.1.3 Preparation methods of co-amorphous systems 
Three types of preparation methods have been reported in the literature for preparing co-amorphous 
systems: thermal method (melt-quenching), solvent evaporation method and milling method. 
Melt-quenching is a method which can be used for production of small quantities of co-amorphous 
materials. In order to produce the amorphous materials, the melt needs to be subsequently vitrified by 
rapid cooling (Lenz et al., 2015). Milling method is one of the most widely used techniques for 
preparation of co-amorphous materials. The advantage of ball milling is that low chemical degradation 
and high recovery compared to other preparation methods (Jensen et al., 2014). However the ball 
milling may not always be easy to break crystal lattice and the purity of co-amorphous materials is 
often questionable. The solvent evaporation method is another method that can be used for large-scale 
preparation of co-amorphous materials. For example, this method was successfully used for the 
preparation of indomethacin and arginine co-amorphous system (Lenz et al., 2015). However, suitable 
solvent selection could be challenging for both components. Moreover, solvent residues within the 
co-amorphous samples could also lead to stability problem during the storage process (e.g. 
recrystallisation) and safety concerns. 
 
Similar to the amorphous materials, the physicochemical properties of co-amorphous materials are 
often affected by the preparation methods. Lim., et al compared the co-amorphous systems of 
indomethacin-cimetidine and naproxen-cimetidine prepared by ball milling, co-evaporation and 
quench cooling methods (Lim et al., 2016). The molecular mobility for three methods is different. The 
molecular mobility of the naproxen-cimetidine samples followed the order co-evaporation (ln τ(β) = 
0.8), quench cooling (ln τ(β) = 1.6) and ball milling (ln τ(β) = 1.8) indicating faster relaxation of ball 
milled co-amorphous than quench-cooled and the co-amorphous prepared by solvent evaporation has 
the slowest relaxation process. Experimentally, all samples can be stored as co-amorphous systems up 
to 7 months (Lim et al., 2016). 
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1.1.4 Physical stabilities of co-amorphous systems 
Many co-amorphous examples have been reported in the literature in terms of improved physical 
stability than the individual amorphous drugs (Dengale et al., 2016). There are several factors can 
contribute to this observed stability improvement. Intermolecular interactions between the components 
in the co-amorphous mixture, such as hydrogen boding and π–π interaction, have been one of the main 
factors discussed in the literature (Alleso et al., 2009; Lobmann et al., 2011; Suresh et al., 2014). 
Similar intermolecular interactions are also observed in drug-excipient co-amorphous systems 
(Dengale et al., 2016). For instance, citric acid has recently been shown strong potential to stabilize 
drugs in the co-amorphous form. Wang., et al prepared co-amorphous formulations of loratadine and 
citric acid (Wang et al., 2017). The results showed the co-amorphous of loratadine-citric acid system 
(molar ratio 1:1) was stable after 90 days at 25°C under both 0% and 60% RH, which is more stable 
than amorphous loratadine (Wang et al., 2017). For the loratadine-citric acid co-amorphous systems, 
hydrogen bonding was found to be responsible for the increased physical stability. Similar physical 
stability enhancement was observed intranilast and diphenhydramine hydrochloride co-amorphous 
systems. The individual amorphous recrystallized within 1 day, whereas the co-amorphous systems 
were stable for up to 30 days (Ueda et al, 2016). 
 
1.1.5 Dissolution advantage of co-amorphous systems 
Improvement in the dissolution rate is another advantage of the co-amorphous material. Shayanfar et 
al. demonstrated that the dissolution rate of atorvastatin calcium could be improved by the formation 
of the co-amorphous formulation of atorvastatin calcium and nicotinamide (Ueda et al., 2016). 
Furthermore, the oral bioavailability of the drugs also can be improved by the use of their 
co-amorphous systems. For example, the oral bioavailability of the co-amorphous talinolol-naringin 
1:1 was significantly higher than crystalline talinolol (Teja et al., 2015). Figure 1.2 summarises the 
proposed underpinning mechanism of the physical stability and dissolution enhancement associated by 
the formation of co-amorphous systems.  
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Figure1.2 The advantages of co-amorphous systems (Chavan et al., 2016) 
 
 
1.2 Solid dispersion 
1.2.1 Definition of solid dispersion 
Over 5 decades ago Sekiguchi and Obi made a eutectic mixture of chloramphenicol and urea by the 
melt method (Sekiguchi and Obi, 1961). The formulation showed that the dissolution rate and 
bioavailability increased when the drug and carrier were cooled from melting (Sekiguchi and Obi, 
1961).This is the first demonstration of solid dispersion as a formulation method for poor soluble 
drugs. Solid dispersion in the literature was first defined as “the dispersion of one or more active 
ingredients in an inert carrier or matrix at solid state by the melting (fusion), solvent or 
melting-solvent method” (Chiou and Riegelman, 1971). Since the introduction of solid dispersion, the 
technology can not only enhance the solubility of the drug and bioavailability, but also is used to 
control drug release and target drug delivery (Crowley, 2007). For instance, the drug has 
characterization of controlled drug release and enteric feature when the drug made by insoluble 
polymer or enteric polymer (Huang et al., 2008).  
 
1.2.2 Types of solid dispersion 
Solid dispersion by definition is a wide range of materials with different molecular level arrange of the 
API and excipients. There are often loss uses of terminology of sub-species of solid dispersions. 
Figure 1.3 summarised the sub-types of solid dispersions. Here the 3 most commonly studied solid 
dispersions are discussed in further detail as below.  
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Figure 1.3 Classification of solid dispersions based on the physical state and distribution of 
phases (Vo et al., 2013) 
 
Eutectic mixtures 
The eutectic mixture usually prepared by drug and carrier. It can be melted with suitable ratio and low 
temperature, followed by cooling to solidification immediately. In the eutectic mixture, the dispersion 
of drugs is of the form of extremely small crystals in the carrier. Thermodynamically, such system is 
regarded as an intimately blended physical mixture of its two crystalline components (Savchenko, 
1959). Some of poorly water-soluble drugs showed to form eutectic mixtures with excipients so that 
enhance their dissolution properties. For example, Yong et.al reported that ibuprofen dissolution rate 
was improved by eutectic mixture formation with menthol resulting in a significant improvement in 
the initial plasma concentration of the drug (Gala et al., 2015). 
 
Solid solution 
Compared to the eutectic mixtures, solid solution is made of a solid solute (drug) dissolved in a solid 
solvent (often polymeric excipients). It is shown that two components are crystalized and mixed 
together in the homogeneous one-phase system. That is the reason why it is also called mixed crystal 
(Savchenko, 1959). The dissolution rate of poorly soluble drugs can be enhanced when the poorly 
soluble drug is in rapidly soluble carrier and the dissolution rate of solid solution is faster than that of 
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the eutectic mixture because the particle size in solid solution has already decreased to minimum 
(Mollan, 2003). 
 
Glass solution 
The glass solution can be defined as the drug is either molecularly dispersed as single phase (glass 
solution) or phase separated mixtures in which the drug present as amorphous domains and/or 
crystalline fraction distributed in an amorphous polymer or polymeric blend (Yee, 2013). The reason 
why the researchers focus on glass solution is that the mixtures can significantly improve the 
dissolution rate of drugs owning to the amorphous nature of the system. Because the amorphous 
systems lack repetitious order, the molecules in such systems are distributed randomly which makes 
the incorporation of the drug in the interstitial spaces between the polymer chains easier compared to 
crystalline polymers. Therefore, amorphous systems exhibit a characteristic behaviour of existing in 
the solid-like (glass) and liquid-like (supercooled liquid or rubbery) states.  
 
1.2.3 Preparation of solid dispersion 
 
Thermal fusion method 
The process of melting means that the drug and a carrier are mixed and heated to melt, then rapidly 
cooled under violent stirring to generate solid dispersions (Sekiguchi and Obi, 1961). The melting 
method is simple and low-cost, but only suitable for the thermally stable drugs. Normally, these solid 
dispersions use either amorphous carriers or crystalline carriers with low melting points (Savchenko, 
1959). 
 
 
Solvent evaporation methods 
The solvent evaporation method can be translated into a range of scalable manufacturing processes 
including freeze drying (Xu W-J et al., 2016), rotary evaporation (Bennett et al., 2015), spray drying 
(Bennett et al., 2016), electrospinning (Tipduangta et al., 2016), electrospraying (Jahangiri et al., 2016) 
and supercritical fluid process (SCF) (Potter et al., 2015). For the solvent evaporation method, the 
physical mixture of drug and polymer is dissolved in a common solvent, followed by the solvent 
evaporation and drying. The solvent method is suitable for the thermally liable drugs. However, higher 
cost of preparation and environmental concerns of solvent wastes are the main disadvantages of this 
method. In addition, incomplete solvent removal from the result solid dispersions could lead to safety 
issues of the product. 
 
Hot-melt extrusion method (HME) 
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HME is a widely used technology in the plastic industry. It has been used to manufacturing a range of 
pharmaceutical products that are mainly solid dispersion based formulations. HME is a heating-based 
method for preparation of solid dispersions without solvent. The pharmaceutical HME process can be 
described as conveying raw materials with rotating screw under elevated temperatures, and products 
with a special shape (determined by the die) can be collected at the end of the extruder. In the late 
1930s, twin-screw extruders were invented in Italy (Tachibana and Nakamura, 1965) and it is main 
type of HME used in pharmaceutical industry. As the name implied, twin-screw extruders have two 
screws arranged side by side. The screws can either rotate in the same or opposite direction 
(co-rotation and counter-rotation, respectively). A pharmaceutical extruder consists of a control panel, 
an inlet feeding hopper, a steel barrel with different heating zones, screws for extrusion, a die attached 
to the end to specially shape the products, and a cooling system, as illustrated in Figure 1.4. However, 
the lab-scale twin-screw extruder used in this project does not have various heating zones. During the 
process of hot-melt extrusion, there is only one temperature that can be operated by the machine. At 
the end of screws, a valve can be closed to make sure the drugs and polymers are mixed completely 
during the process of extrusion. By blocking the outlet, the material can be circulated through the 
mixing zone at a constant temperature.  
 
Basically, the HME formulation can be separated three components including drugs, polymer and 
plasticizers. During the HME process, the polymer should be soften or molten. For the plasticizers, it 
necessary to ease the HME process when the HME system are viscous.  
 
The main application for hot melt extrusion in pharmaceutical industry include fast release 
formulation and sustained release formulation. By using hot melt extrusion, fast release formulation 
are based on the preparation of amorphous solid dispersion (Kalivoda, Fischbach and Kleinebudde, 
2012). The poorly water soluble drug dissolution rate can be improve significantly because of use 
HME to process drug and polymer mixtures into amorphous solid dispersion. For example, a study 
shows itraconazole and hydroxypropylmethyl-cellulose (HPMC) 2910 solid dispersion were prepare 
by HME and its amorphous solid dispersion were confirmed by MTDSC and PXRD(Rambali et al., 
2003). In this study, Itraconazole is a typical BSC II drug with low solubility (1.8ug/ml in PH 1.2 
solution) (Jung et al., 1999). The results shows the drug release of formulation was reached to 90% 
after 120min under sink condition (Rambali et al., 2003). By using hot melt extrusion prepare solid 
dispersion with water insoluble polymeric carriers, the drug release can be sustained from 
formulations (Yang et al., 2008). A report shows that using twin-screw hot melt extruder to prepare 
controlled release diclofencsodium formulation with different matrices (Sato et al., 1997). The results 
shows that the dissolution rate can be controlled by adjusting the drug loadings (Sato et al., 1997). 
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Figure 1.4 A schematic illustration of a twin screw hot-melt extruder (Jani and Patel, 2015) 
 
1.2.4 Physical stabilities of solid dispersions 
Despite some of advantages of solid dispersion for improving dissolution rates of drugs, poor 
long-term physical stability is the common drawback of solid dispersion. The main consequence is 
drug recrystallization which reduces the dissolution rate of the drug in the solid dispersion formulation. 
For instance, due to the stability problem of solid dispersion formulation, Norvir, which is solid 
dispersion product of an antiviral drug Ritonavir from Abbot, was withdrawn from the market (Mooter 
et al., 2001). There is a wide range of factors contributing to the often observed poor stability of solid 
dispersion. Moisture is one of the major factors affecting the solid dispersion stability. A research 
showed that the reason why moisture can effect physical stability of solid dispersion (Andronis et al., 
1997). The moisture in the solid dispersion could increase the molecular mobility so that it increased 
the rate of recrystallization of the API in the solid dispersion. Therefore, the selection of appropriate 
storage condition is extremely important for the stability of solid dispersions. For instance, A paper 
showed that the solid dispersion of nifedipine, nicotinamide and HPMC were stored in the 
environment at 30 C with 60% and 75% RH for a month (Suzuki and Sunada, 1998). The 
recrystallization of nifedipine led to the great reduction of the drug dissolution rate. However, the solid 
dispersion of nifedipine, nicotinamide and HPMC did not change the state when stored at drying 
environment even with higher temperature. Guillaume., et al reported that if the solid dispersion of 
oxodipine and PVP was stored at a relative humidity less than 55% at different temperatures, there 
was no crystallization occurs within the solid dispersion (Suzuki and Sunada, 1998). However the drug 
recrystallization occurred when the storage environment was at 80% RH.  
 
The thermodynamic instability of the solid dispersions is originated from the molecular mobility of the 
systems. The glass transition temperature (Tg) is one of the indictors of the potential physical 
instability of the solid dispersions. Tg is defined as a kinetic parameter where the transformation of 
material form from glassy state to a super cooled liquid state upon heating. The amorphous material 
has an increased viscosity when the amorphous material below glass transition temperature and the 
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mobility of molecular are decreased. This phenomenon helps amorphous material ‘relaxes’ into their 
thermodynamically stable form and this process is called molecular relaxation(Hancock et al., 
1997).For a glass solution or often called an amorphous solid dispersion, a single Tg should be 
detected, if the binary system is miscible. If more than one Tg are detected, it indicates the system 
having phase separation (Craig et al., 2000). For a miscible system, the Tg of the dispersion should be 
between the Tg of the individual compound. As an example, using higher Tg amorphous polymers 
could potentially enhacne the physical stability of amorphous solid dispersions compared with 
amorphous drugs alone due to the anti-plasticisation effect of the polymer (Serajuddin, 1999). 
 
The Tg of the miscible amorphous dispersions can be predicted using Gordon-Taylor (G-T) equation, 
which is expressed using Eq. 1.1 
 
                       Tgmix = [(w1Tg1) + (Kw2Tg2)] / [w1 + (Kw2)]                  Eq. 1.1 
 
whereTgmix is the glass transition temperature of mixture, Tg1 and Tg2 represent the glass transition 
temperature of individual component respectively. w1 and w2 are the weight fraction of each 
component. K is a constant which can be describe as: 
 
                                 K ≈ (ρ1Tg1) / (ρ2Tg2)                           Eq. 1.2 
 
Where ρ1 and ρ2 represent the true density of individual component. The G-T equation can be used to 
make comparison between theoretical glass transition temperature and experimental glass transition 
temperature. Because the G-T equation is based on the assumption of ideal mixing in which the 
molecules from the two components are blended completely. In the literature it was recognised that if 
theoretical glass transition temperature and experimental glass transition temperature are deviated, it 
may indicates interactions between the components depending on whether the deviation being 
negative or positive (Shamblin et al., 1998).  
 
1.3 The objectives of this study 
The main aim of this study is to enrich the existing knowledge of co-amorphous materials by gaining 
more in depth knowledge of the physical stability of co-amorphous systems. There are 2 main 
objectives of this MSc project:  
 Investigate the physical stability of co-amorphous material and provide insights into the impacts 
of molecular interactions on the physical stability of co-amorphous systems 
 Investigate the stabilisation capability of amorphous polymeric dispersions for co-amorphous 
drugs 
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Chapter 2 Materials and methods 
 
2.1 Introduction  
In this chapter the key physicochemical properties of the two model drugs and main polymeric 
excipients will be analysed and discussed. This information is ready used in the following chapters for 
interpreting the behaviour of the co-amorphous and solid dispersion stabilised co-amorphous systems. 
Serveral of characterisation technologies were used for physicochemical properties of amorphous solid 
dispersion. For example, Differential Scanning Calorimetry (DSC) results presenting a single glass 
transition which may indicates a single-phase amorphous solid solution (Verdonck et al., 1999). A 
amorphous halo detected by Powder X-ray Diffraction (PXRD) may indicates the majority of samples 
in the solid dispersion was mainly amorphous (Margarit et al., 1994). Moreover, Fourier Transform 
Infrared Spectroscopy (FTIR) can be uesed judge the intereaction between drugs and polymer by 
analysing peak position (Larkin, 2011). So, a brief introduction of the methodologies used for 
characterisation in this project is also discussed in this chapter.  
 
2.2 Materials 
2.2.1 Felodipine 
Felodipine (1,4-dihydropyridine) (Figure 2.1a) a long-acting calcium channel blocker with poor 
aqueous solubility (Patil et al., 2009) was purchased from Afine chemicals Ltd. (Hangzhou, China). 
For crystalline felodipine, four polymorphic forms have been reported in literature. The melting point 
for forms I-IV are 143.8 ± 0.2C, 134.8 ± 0.2C, 143.7 ± 0.2C and 145.7 ± 0.2C respectively (Surov 
AO et al, 2012). The NH group and C=O group can be detected by ATR-FTIR with different forms. 
For crystalline felodipine, the NH peaks were reported at 3372,3334, 3370, 3329 cm-1 for crystalline 
felodipine form I, II, form III and form IV, respectively. The NH group of amorphous state felodipine 
was detected at 3339 cm-1. IRwas also able to detect inter-molecular hydrogen-bonded C=O stretching 
and non-hydrogen bonded C=O peaks for form I, II and IV (Lou B, 2009). For NH group and 
hydrogen-bonded C=O stretching peaks were reported at 1690, 1683 and 1654 cm-1. On the other hand, 
non-hydrogen bonded C=O group of form I, II, IV were detected at 1699, 1698, 1703 cm-1, 
respectively. For IR spectra of hydrogen-bonded C=O stretching peaks and non-hydrogen bonded 
C=O group peaks of amorphous felodipine was 1682 and 1701 cm-1(Wang et al., 2015).  
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Figure 2.1 Chemical structures of paracetamol and felodipine 
 
2.2.2 Paracetamol 
Paracetamol is a non-steroid anti-inflammation drug used to control mild-moderate pain or to reduce 
opioid exposure as part of multimodal analgesia. It is typically used for mild to moderate pain. 
Paracetamol used in this project was purchased from Sigma-Aldrich Company Ltd. (Dorset,UK). 
Three polymorphs of crystalline paracetamol have been reported in literature. The melting point of 
form I is 170C, 159C for form II, 143C for form III, respectively (Simon et al., 2010). In the IR 
spectra, crystalline paracetamol form I has O-H peaks at 3321cm-1, N-H bond at 3157cm-1, and C=O 
bond at 1650cm-1 as its key characteristic peaks.  
 
2.2.3 Soluplus 
Soluplus (Figure 2.2), is a graft amorphous polymer which has a low glass transition temperature 
(approximately 70 °C) and purchased from BASF (Ludwigshafen, Germany). Sodium chloride and 
hydrochloric acid were purchased from Sigma-Aldrich Company Ltd (Dorset, UK). All the organic 
solvents and water were of high-performance liquid chromatography (HPLC) grade. Felodipine has 5 
hydrogen bond acceptors and 1 hydrogen bond donor, whilst Paracetamol has 2 hydrogen bond 
acceptors and 2 hydrogen bond donors. Together, they are a suitable combination of model drugs 
because there is the potential of hydrogen bonding formation, which benefits stability and the 
formation of a co-amorphous system and solid dispersion system. 
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Figure 2.2 Chemical structure of the monomer of Soluplus 
 
2.3 Methods 
2.3.1 Differential scanning calorimetry (DSC) 
DSC is an essential technique for thermal analysis of materials. DSC was first commercially 
introduced in 1963 and it also usually be used in development of pharmaceutical materials. (Theeuwes 
et al., 1974). The theory of DSC method is that the detection of thermal transitions events of materials 
like melting, crystallization, glass transitions, and decomposition reactions (Verdonck et al., 1999). 
Generally, there are two parts of DSC instruments which is power compensation and heat flux. For the 
power compensation DSC, two separated furnaces can be used for the reference and for the sample 
and both of them are heated and maintained at the same temperature. Compare to power compensation 
DSC, the heat flux DSC uses two pans (crucibles) for the sample and for the reference within one 
furnace as seen in Figure 2.2 and the heat flux DSC will be used for this project. They are both heated 
from the same temperature program and the temperature difference between the sample and the 
reference is measured (Duncan and Craig, 2008).  
 
Heat flow from the furnace to each crucible can be explained in Eq. 2.1 
 
                                   dQ/dt = ΔT /R                              Eq.2.1 
 
whered Q / dt is the heat flow. ∆T is the temperature difference between the sample and the reference 
and R is the thermal resistance of the heat paths between the furnace and the crucible. The total heat 
content of a material is in linear relationship to its heat capacity (Cp J/g·C) which is the quantity of 
heat required to change the temperature of the material by 1K:  
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                                   Cp =dQ / dT                               Eq 2.2 
 
  Rearranging this equation with time:  
 
                                  dQ / dt = Cp (dT / dt)                         Eq 2.3 
 
where dQ / dt is the heat flow and dT / dt is the heating rate. With this equation, the differential  
heat flow can be a measure of the sample heat capacity. DSC data is normally expressed with the  
heat flow as a function of the temperature. 
 
In this study, a Q-2000 DSC equipped with a RC90 cooling unit (TA Instruments, Newcastle, USA) 
was used to perform all thermal analysis shown in Figure 2.3. A full range of temperature and heat 
capacity calibrations were performed prior to sample measurements. Approximately 2 – 5 mg of 
samples were weighed and sealed into the aluminium pans and lids (TA Instruments, Newcastle, USA). 
10 C/min heating rate was used for all samples. All samples were tested in at least triplicate.  
 
Figure 2.3 Illustration of working mechanism of heat flux DSC (Kodre et al., 2014) 
 
2.3.2 Attenuated Total Reﬂectance-Fourier Transform Infrared Spectroscopy (ATR-FTIR) 
FTIR is one of technique that can be used to identify chemical structure of different materials. By 
using the mid-infrared electromagnetic radiation within the wavenumber range of (4000-400 cm-1), 
The Chemical bonds in molecules can be stretched so that the radiations can be absorbed and stimulate 
molecular vibrations and rotations at specific frequencies (Watson, 2012). 
 
 Chapter 2                                               Materials and methods 
 26 
The principle of ATR-FTIR is shown in Figure 2.4. ATR-FTIR method is based on a high refractive 
index crystal such as diamond is used (Schuttlefield and Grassian, 2008). The sample for investigation 
could be liquid or solid. And the sample can be placed in contact with the diamond, and infrared light 
from an FTIR source is allowed entering the diamond at a specific angle and reflecting at the surface 
(Schuttlefield and Grassian, 2008). There are several benefits of ATR-FTIR for material investigation. 
The main advantage is that this method is time-saving compare to other technique and no need for 
further sample preparation. The depth of penetration dir, defined as the distance normal to the 
interface which the intensity falls to 1/e of the intensity at the surface, is expressed in Eq. 2.4 
 
dir = λ / (2πn1 (sin2 θ – n122)1/2)                     Eq. 2.4 
 
where λ is wave length of IR beam, np is the refractive index of the ATR crystal, θ is the angle of 
incidence of IR radiation, and nsp= n2/n1 is the ratio of the refractive indices between the sample and 
the internal reflective element (crystal) (Larkin, 2011). 
 
Figure 2.4 Schematic illustration of using ATR-FTIR method to test a sample (Larkin P,2011) 
 
In this study, all of experiments were conducted using an IFS 66/S FTIR spectrometer (Bruker Optics 
Ltd., Coventry, U.K.). It is also fitted with a Golden Gate ATR accessory (Specac, Orpington, U.K.) 
equipped with diamond internal reﬂection element. All ATR-FTIR spectra were obtained using a 
scanning resolution of 2 cm−1 with 32 repeated scans in the absorbance mode. OPUS software (Bruker 
Optics Ltd., Coventry, U.K.) was used for spectra analysis. The variable temperature ATR-FTIR 
experiments were carried out using the same instrument set-up. The ATR sample stage was heated up 
from room temperature to 20C at 190C/min. 
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2.3.3 Powder X-ray Diffraction (PXRD)  
PXRD is a method to analysis the crystal lattice parameter, crystal defect, content of drug or 
formulations (Serajuddin, 1999). The diffraction will occur if a crystalline material is interacted with a 
focused X-ray beam according to Bragg’s law, 
 
nλ = 2dsinθ                            Eq. 2.5 
 
where d represent the interplanar spacing of the diffracting planes. θ represent the incidence angle of 
X-rays and n is an integral number of wavelengths, and λ is the wavelength of the incident X-ray 
beam. 
 
PXRD is considered a fundamental tool for the pharmaceutical solid dispersions research and product 
development. The main advantage is that the physical state of a solid dispersion can be rapidly tested 
being amorphous or crystalline as well as identification of polymorphic forms of crystalline materials 
(Margarit et al., 1994). If no diffraction peaks can be detected by PXRD, the system can be considered 
as ‘PXRD amorphous’. However, caution should be taken during data analysis as nano-crystal 
diffraction patterns may also appear as amorphous halo without processing using pair distribution 
function (PDF) (Margarit et al., 1994).  
 
In this study, a Thermo ARLXtra X-ray diffractometer (Thermo Scientific, Switzerland) equipped 
with a copper X-ray tube (λ = 1.540562 Å) were used for all sample analysis shown in Figure 2.5. The 
samples were measured using an X-ray beam with voltage of 45 kV and a current of 40 mA. The 
angular scan range was (5 ° <2 θ <60 °) using a step scan mode with step width of 0.01 ° and scan 
speed of 1s/step. 
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Figure 2.5 Diagram of powder X-ray diffractometer (Morris et al, 2011) 
 
2.3.4 Scanning electron microscopy (SEM)  
SEM is a type of electron microscope that used for investigating morphology of the samples at a 
micron to submicron scale. It has high magnification compare to the normal light microscopes. The 
interactions between the beam and the atoms in the sample can be detected by scanning the sample 
with a high-energy electron beam. In this work, AJSM5900LV field emission scanning electron 
microscope (Jeol Ltd., Japan) equipped with a tungsten hairpin electron gun was used to visualize the 
surfaces and the cross sections of solid dispersion. To avoid damaging the surfaces of the solid 
dispersion, the samples can be used directly for the investigation of surface of the sample. Before 
imaging, the samples have to attached onto SEM specimen stubs by double-sided tape and coated with 
gold using a Polaran SC7640 sputter gold coater (Quorum Technologies, East Sussex, UK). 
 
2.3.5 Thermogravimetric Analysis (TGA)  
TGA refers to analysis on the relationship between temperature and weight of the solid dispersion with 
the program that can control temperature. It is usually used to study the thermal stability of materials 
and components. TGA in research is a relatively common means of detection for the drug 
development. In this study, at a heating rate of 10 C/min to 250 C were used to study the thermal 
degradation behavior of the samples. A TGA Q500(TA Instruments, New Castle, DE) was used for all 
sample measurements. All samples were tested in at least triplicate.  
 
2.3.6 In vitro drug release studies 
The dissolution testing apparatus (Caleva ST, Germany) with BP paddle method was used to test the 
in vitro drug release profile of the co-amorphous and dispersion formulations. For all measurements, 
using paddle rotation speed of 100 rpm and 900 ml of hydrochloric acid (HCl) with pH 1.2 (simulated 
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gastric fluid) at 37 °C ± 0.5 °C. Then, the samples should be filtered by filtration membrane of 0.22μm 
pore size (Minisart NML single use syringe, Sartorius, UK). After sampling, 5ml fresh media were 
added back to each dissolution vessel. Finally, a UV − vis spectrophotometer (PerkinElmer lambda 35, 
USA) at 363 nm (for felodipine) and 247 nm (for paracetamol) was used to quantify the drug content 
in each dissolution sample. All drug releases were studied in triplicate. The calibration curves of 
paracetamol and felodipine are shown in Figure 2.6. 
 
Figure 2.6 UV calibration curves of paracetamol (a) and felodipine (b) 
2.4 Solid-state characterisation of the raw materials 
The crystalline paracetamol and felodipine as well as the polymer, Soluplus, used in Chapter 5 for 
preparing the solid dispersions were characterised using DSC, PRXD, SEM and ATR-FTIR. The 
ATR-FTIR spectra of crystalline paracetamol and felodipine will describe in Chapters 3 and 5 when 
they were compared to the spectra of co-amorphous and solid dispersion systems. The melting of the 
crystalline model drugs and their glass transition temperatures were studies using DSC 
heat-cool-reheat method. The scanning rate was 10C/min. The melting point of crystalline 
paracetamol and felodipine is determined as 147 C and 169 C, respectively, indicating being form I 
for both. As shown in Figure 2.7, the glass transition temperatures were detected for both of model 
drugs at 26 C and 47 C for amorphous paracetamol and felodipine, respectively. Amorphous 
paracetamol recrystallized upon reheating and melted at 158 C, which indicates the recrystallization 
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of paracetamol form II. The DSC result of Soluplus shows the Tg of 73.6 C, which agrees well with 
the literature, reported values (Mohammad and Steven, 2016). It is also noted that Soluplus contained 
some level of moisture, thus a clear water loss endothermic peak is observed in the first heating cycle.  
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Figure 2.7 DSC results of crystalline paracetamol (a) felodipine (b) and Soluplus (c) 
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Figure 2.8 shows the PXRD of crystalline paracetamol, felodipine and Soluplus. It can be seen that the 
paracetamol and felodipine are in full crystalline form. After comparing with the literature data, the 
PXRD results confirmed again that both paracetamol and felodipine were in their polymorphic form I. 
The PXRD result of Soluplus shows being a fully amorphous halo. 
 
Figure 2.8 PXRD results of crystalline paracetamol, crystalline felodipine and Soluplus 
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The SEM images of crystalline paracetamol, felodipine and amorphous Soluplus are shown in Figure 
2.9. As seen in the SEM images, paracetamol shows needle-like crystals, whereas felodipine crystals 
are mainly in cubic shape. Soluplus particles show rough but round edges which may be attributed to 
its amorphous nature.  
 
Figure 2.9 SEM images of crystalline paracetamol (a), crystalline felodipine (b) and (c) Soluplus 
 
2.5 Thermal analysis of physical mixtures of crystalline paracetamol and felodipine 
The physical mixtures of the two crystalline drugs were prepared by pestle and mortar mixing with a 
range of w/w rations from 1:9 to 9:1. It should be highlighted here that the w/w 3:7 and 7:3 of 
felodipine-paracetamol is close to the molar ratio of 2:1 and 2:1 used later in the co-amorphous study. 
The purpose of this part of the study is to investigate the miscibility of the two drugs. As reported in 
the literature, if the two compounds having good miscibility, the melting point depression 
accompanied by reduced melting enthalpy can often be observed for the crystalline material. As seen 
in Figure 2.10, instead of melting point depression, a new melting point (peak temperature) at 133 C 
was detected for all physical mixtures. This new melting was initially associated with the possibility of 
forming eutectic of the two drugs. However, this was not possible as with all mixing ratios, the new 
melting was observed. So this indicates that the new melting is not associated with eutectic mixture of 
the two drugs as eutectic system normally only forms at eutectic point with a specific mixing ratio of 
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the two compounds. The enthalpy of this new melting point changes with the weight ratio of 
paracetamol to felodipine in the mixes. As seen in Figure 2.11, there seems to be a linear correlation 
between the melting enthalpy (indicating the quantity of the new species) and the w/w ration of the 
two model drugs. It is not clear why there are two linear regions, 10-40% paracetamol and 50-90% 
paracetamol in the mixtures. Nevertheless, it is noted that the melting enthalpy increases with 
increasing the amount of crystalline felodipine in the mixtures indicating that the new melting is 
highly associated with felodipine rather than paracetamol. Further investigation was carried out with 
the intension to identify the new species with 133 °C melting. Therefore, variable temperature 
ATR-FTIR experiments were performed.  
 
 
Figure 2.10 DSC results of all physical mixtures of crystalline paracetamol and felodipine 
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Figure 2.11 The plot of melting enthalpy of 133 °C peak against the w/w ratio of paracetamol in 
paracetamol-felodipine physical mixtures 
 
The variable temperature ATR-FTIR data are shown in Figure 2.12-14. The 3500-3200 cm-1 regions 
were the key focus for detailed analysis as these regions showed more significant changes in 
comparison to other regions. Within this region, the N-H peak of felodipine and O-H peak of 
paracetamol can be clearly seen. Although there is some overlap, the two peaks can still be 
distinguished as two separate peaks. As seen in Figure 2.12, the N-H peak of crystalline felodipine 
shows more significant changes during heating for the paracetamol-felodipine physical mixture with 
the ratio of 3:7 (w/w). Little changes in the peak shape and intensity were observed for the O-H peak 
of crystalline paracetamol. The N-H felodipine peak at 3371 cm-1 almost disappeared when the 
temperature reached 140C. Instead, a weak peak 3426 cm-1 was gradually developed between 
130-140C. With decreasing the amount of felodipine in the mixtures (Figure 2.13 and 14), the final 
intensity of this new peak is decreased. This again indicates that the formation of the new low melting 
species is associated with felodipine which agrees well with the DSC data. However due to time 
constrain, the identification this new species was not continued further.  
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Figure 2.12 Variable temperature ATR-FTIR spectra of paracetamol:felodipine 3:7 (w/w) 
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Figure 2.13 Variable temperature ATR-FTIR spectra of paracetamol:felodipine 1:1 (w/w) 
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Figure 2.14 Variable temperature ATR-FTIR spectra of paracetamol:felodipine 7:3 (w/w) 
 
2.6 Conclusion 
This chapter introduced the basic physicochemical properties of the model drugs and polymer used in 
this project. All the characterisation methods were also introduced in terms of their basic working 
mechanisms and the generic methods used in the project. The characterisation of the amorphous drugs 
agreed well with the literature data. Interesting data were generated when the physical mixtures of the 
crystalline model drugs were studied. A new species related to felodipine was generated during the 
heating of the crystalline physical mixture of the two model drugs. Whether this new low melting 
species is a polymorphic form of felodipine is unclear and was not further investigated within the 
timeframe of this project. However, it is unlikely to be the depressed melting of felodipine form I as 
the variable temperature ATR-FTIR results showed the development of a new N-H peak with a shift to 
a higher wavenumber than the felodipine form I.  
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Chapter 3 Preparation and characterisation of freshly prepared 
co-amorphous systems 
 
3.1 Introduction 
As discussed in Chapter 1, co-amorphous systems are considered an effective method used to improve 
poor dissolution problem. With the understanding established in Chapter 2 on the physical mixtures of 
the two model drugs, the co-amorphous systems of the two drugs are the focus of this chapter. The 
objectives of this chapter are preparing the co-amorphous system samples with different molar ratios 
of paracetamol and felodipine (1:1, 1:2 and 2:1) and performing solid-state characterisations of the 
co-amorphous sample. 
 
3.2 Methods 
3.2.1 Preparation of co-amorphous systems 
In this study, physical mixture of crystalline paracetamol and felodipine (PF) was prepared with 
different molar ratios of 1:1 (PF 1:1), 1:2 (PF 1:2) and 2:1 (PF 2:1) in aluminium dishes. The heater 
plate was preheated to 170C. The dishes containing the physical mixes were then placed on the heater 
plate to allow both drugs melted completely. Isotherm heating was held for 7 minutes to ensure that no 
drug particle was visible in aluminium dishes. Finally, air cooling the samples by removing the dishes 
off the heater plate to the bench surface immediately (room temperature about 20C). The samples 
were stored indifferent chambers with relative humidity (RH) of 75% RH/40C and 0% RH/room 
temperature(RT) for further stability studies (Chapter 4). 
 
3.2.2 Characterisation of the co-amorphous systems 
SEM, PXRD, DSC and ATR-FTIR were used to characterise the freshly prepared co-amorphous 
systems. The detailed methods were described in Chapter 2.  
 
3.3 Results and discussion 
3.3.1 Visual observation of the PF co-amorphous system samples 
The freshly prepared PF co-amorphous samples are shown in Figure 3.4. All samples immediately 
after preparation show yellow glassy appearance with smooth surface and no crystals can be observed.  
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Figure 3.1 Visual observation of the freshly prepared PF co-amorphous 1:1(a), 1:2(b) and 2:1(c) 
 
3.3.2 DSC  
The DSC results of PF co-amorphous systems were different from two model drugs. As describe in 
Chapter 2, the melting points of crystalline paracetamol and felodipine are 169C and 145C, 
respectively. In the co-amorphous samples, no original crystalline drug melting can be detected for PF 
co-amorphous 1:1 and 1:2 systems. However, it can be seen in Figure 3.2that the PF co-amorphous 
system 2:1 shows an endothermic transition at 152C which is likely to be the depressed melting of 
paracetamol form II. A clear exothermic recrystallisation peak with an onset of 95-100 °C can also be 
seen before the melting indicating the likelihood of the significant amount of the melted crystalline 
material was generated by heating induced crystallisation. In contrast, PF1:1 and PF 1:2 only show Tg 
without any detectable melting indicating the full amorphous states of the samples. Paracetamol is 
known in the literature having high tendency of recrystallization and a low Tg= 21 C (Qi et al., 2008). 
As PF 2:1 contains more paracetamol, the recrystallization of amorphous paracetamol may contribute 
to the melting observed in PF 2:1. In the literature, the recrystallization paracetamol form II was 
reported following melt-cool preparation (Shadi and Iba'a, 2011). This could also explain why the 
co-amorphous formulation with high ratio of paracetamol was not stable in the later stability study 
section. The PF co-amorphous systems all have a single Tg which is 35.7, 36.1 and 41.5C, for PF1:2, 
1:1, 2:1, respectively. These Tg values are between the Tg values of amorphous paracetamol and 
felodipine and increasing with the increased felodipine content in the co-amorphous systems. The 
clear single Tg detected for all systems indicates that PF co-amorphous systems were successfully 
prepared by melt-cool method (Swapnil et al., 2016). These Tg were compared to the Tg of the 
mixtures calculated by Fox equation which is a simpler version of Gordon-Taylor (G-T) equation 
(Witold et al., 2008). 
                    1 / Tgmix = w1 / Tg1 + (1-w1) / Tg2                        Eq. 3.1 
where Tgmix is the glass transition temperature of the drug-polymer system, Tg1 is the glass transition 
temperature of component 1 (amorphous paracetamol, 25 C), Tg2 is the glass transition temperature of 
component 2 (amorphous felodipine, 45 C) and w1 is the weight fraction of component 1. 
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According to the Fox equation calculation, the calculated Tg values of the co-amorphous systems are 
shown in Table 3.1. For PF all of co-amorphous system, the measured Tg values negatively deviated 
from the Fox equation predicted values. This indicates that the P-F co-amorphous system is miscible 
and some level of molecular interactions may be responsible for the negative deviation from the 
predicted values (Shamblin et al., 1998). 
 
Figure 3.2 DSC results of freshly prepared P-F co-amorphous system 1:1, 1:2 and 2:1 
 
3.3.3 PXRD  
The fresh PF co-amorphous system samples were tested by PXRD as seen in Figure 3.3. The results 
show that no paracetamol and felodipine diffraction peak can be detected by PXRD. This indicates 
that the freshly prepared PF co-amorphous systems are fully ‘PXRD’ amorphous. The PXRD results 
of PF 2:1 system were not in good agreement with DSC result because by DSC some paracetamol 
crystallisation was detected. This may be due to differences in the sensitivity and detection limits of 
the instruments. It is also possible that the melting observed in PF 2:1 DSC result was originated from 
the drug recrystallized during the heating process of the DSC run instead of having crystalline drug 
present in the sample.  
Table 3.1 Comparison of Tg values of P-F 1:1, 1:2 and 2:1 measured experimentally by DSC 
(cooling cycle) and the predicted values by Fox equation 
 P-F 1:1 P-F 1:2 P-F 2:1 
Experimental Tg (C) 36.1 41.5 35.7 
Predicted Tg (C) 34 39 31 
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Figure 3.3 PXRD of freshly prepared P-F co-amorphous system 1:1, 1:2 and 2:1 
 
3.3.4 ATR-FTIR spectroscopy 
The ATR-FTIR results of the PF co-amorphous system 1:1, 1:2 and 2:1 also showed agreement with 
DSC results. As seen Figure 3.4 (a), pure amorphous felodipine shows single NH group peak at 3331 
cm-1and one peaks shows at 1701 cm-1in carbonyl groups region which is belong to crystalline 
felodipine. For amorphous paracetamol, the peak at 1557 cm-1can be ascribed to a carbonyl group. A 
single NH peak at 3315 cm-1, C=N at 1559 cm-1 and C-O group at 1171 cm-1can also be observed 
(Figure 3.4). The result of PF co-amorphous system 1:1 shows similar NH peak wavenumber as 
prediction result which is 3312 cm-1 for paracetamol. Compare to wavenumber of pure amorphous 
felodipine NH group, the PF co-amorphous system 1:1 shows same results indicating no significant 
hydrogen bonding occurred in the co-amorphous systems. Similar results were obtained for 1:2 and 
2:1 samples.  
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Figure 3.4 ATR-FTIR spectra of freshly prepared P-F co-amorphous systems (a) 1:1; (b) 1:2 and 
(c)2:1 
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3.3.5 SEM 
The SEM results of the freshly prepared PF co-amorphous systems are shown in Figure 3.5. For the 
surfaces of PF 1:1 and 1:2 co-amorphous systems, no paracetamol and felodipine crystal could be 
detected by SEM. However, there are some particles on the surface of the PF 1:1 and 1:2. These 
particles are likely to be the fragmented pieces attached to the surface during the samples preparation 
as they seemed loosely adsorbed on the surfaces of the samples. In comparison to PF 1:1 and 1:2 
co-amorphous systems, the SEM results of PF 2:1 co-amorphous system show some difference and it 
is very clear that the surface of PF 2:1 is not smooth and some drug particles with defined edges 
(likely to be crystalline particles) can be seen on the surface. This is indicated that the PF 2:1 was not 
in amorphous state when the sample were fresh. 
 
For the cross section of these three samples, same results can be seen compare to the surface of 
samples. The cross section of PF 1:1 and 1:2 co-amorphous system shows that no crystal occurred 
when the sample were fresh. As mentioned before, the particles seen on the cross section are 
fragmented solids instead of crystalline drug particles. However, the cross section of PF 2:1 shows 
clearer appearance of drugs particle embedded in the sample than PF 2:1 surface. This indicates that 
PF 2:1 was not fully amorphous. Therefore, the SEM data are in good agreement with the DSC results. 
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Figure 3.5 SEM images of the freshly prepared (a) P-F co-amorphous 1:1, (b) P-F co-amorphous 
1:2, (c) P-F co-amorphous 2:1, (d) P-F co-amorphous 1:1 (cross section), (e) P-F co-amorphous 
1:2 (cross section), (f) P-F co-amorphous 2:1 (cross section) 
  
 
3.3.6 Dissolution 
Figure 3.6 shows the in vitro dissolution behaviour of co-amorphous drug release system 1:1, 1:2 and 
2:1 under pH 1.2 at 37C. For all co-amorphous samples, felodipine showed some dissolution 
improvement than the crystalline drug up to 30 minutes. After 30 minutes, such improvement was 
reduced to similar level as the crystalline drug. This may be attributed to the fact that the amorphous 
felodipine was recrystallized after 30min and the poor solubility of crystalline felodipine. As discussed 
in the Chapter 4 and 5, the amorphous felodipine can be recrystallised easily at certain conditions, for 
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example RH75% and 40°C/RT. During the dissolution experiment, the media environment is 35°C 
and PH 1.2, when the extrudates dissolve in the media, the amorphous felodipine may recrystallised at 
the same time. To prove this point, extra experiments may be needed in the future. For instance, taking 
50ml media after dissolution, drying the sample completely, a few particles may show after drying and 
performed the DSC test. However, paracetamol in P-F co-amorphous systems shows significantly 
higher dissolution rates than felodipine. This is partially because paracetamol has a higher solubility 
than felodipine. However, the dissolution rate of paracetamol in the co-amorphous systems were 
slower than the crystalline paracetamol alone. This dissolution rate shows significant increase in the 
P-F 2:1 system. This is likely due to the high paracetamol content of the systems. For P-F 1:2 and 1:1, 
the slower dissolution than the crystalline paracetamol could be attributed to the entrapment of 
amorphous paracetamol within the crystallised felodipine which hindered the dissolution of 
paracetamol.  
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Figure 3.6 Dissolution of freshly prepared co-amorphous P-F 1:2(a), 1:1(b) and 2:1(c) 
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3.4 Conclusion 
In this chapter the freshly prepared co-amorphous P-F 1:1, 1:2 2:1 samples were investigated. 
According to the DSC results, all three co-amorphous systems formed homogeneously mixed 
amorphous materials with a single Tg. Little evidence shown in the ATR-FTIR results suggested 
extensive interaction between paracetamol and felodipine. This indicates the co-amorphous systems 
were formed simply as mixtures of paracetamol and felodipine molecules blended together in their 
amorphous state. This may explain the poor dissolution enhancement of felodipine in the 
co-amorphous systems. Due to the recrystallization of felodipine in the co-amorphous system during 
dissolution, the dissolution rate of paracetamol was reduced due to the entrapment of paracetamol 
molecules in the crystallised felodipine. The physical stability of the co-amorphous system will be 
investigated in the next Chapter.  
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Chapter 4 Physical stability studies of co-amorphous systems 
 
4.1 Introduction 
Despite the dissolution enhancement was not observed in the model systems studied in this project, the 
co-amorphous systems enhancing the dissolution rate for poorly water-soluble drugs has been reported 
in literature (Dengale et al., 2016). However the preservation of the long-term physical and chemical 
stability of the co-amorphous systems still remains the main challenge for the formulation scientists. 
As discussed in Chapters 2 and 3, paracetamol has low a Tg and showed high recrystallization 
tendency in the co-amorphous systems with high paracetamol content. This may be related to the 
supersaturation of paracetamol in the co-amorphous mix. In order to rationalise the formulation 
strategy for improving the physical stability of co-amorphous systems, it is important to first 
understand their physical instabilities in a great depth. In this chapter, three of co-amorphous samples 
were prepared and then aged under two different storage conditions, 0% RH/room temperature (RT) 
and 75% RH/40oC, for up to two weeks. The rationale of the selections of these 2 conditions was to 
provide understanding on the physical stability of co-amorphous system at two highly contrast storage 
conditions.  
 
4.2 Methods 
4.2.1 Storage condition 
Co-amorphous system samples were stored in two different aging conditions, 75% RH/40 C and 0% 
RH/RT. The samples stored in a desiccator containing saturated sodium chloride in ultrapure water to 
achieve 75% RH. The desiccator was incubated at 40oC. The samples were also stored in a desiccator 
with 0% RH (provide by P2O5) at room temperature. Characterisation tests were performed after 1, 3, 
7 and 14 days to detect any change in physical state of the co-amorphous samples. 
 
4.2.2 Physicochemical characterisation 
DSC, PXRD and ATR-FTIR were used for monitoring physical stability of co-amorphous system. The 
detailed methodologies were described in Chapter 2. 
 
4.3 Results and discussion  
4.3.1 Physical stability of PF co-amorphous system under 0% RH/RT 
4.3.1.1 DSC 
Physical stability of PF co-amorphous systems under 0% RH/RT were studies using DSC in the first 
instance. After 7days aging, all three co-amorphous systems still show clear Tg indicating the 
significant amount of amorphous contents in the samples. The clear melting of crystalline compound 
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can be only detected in PF 2:1 samples. As seen in Figure 4.1a, a broad exothermic crystallisation 
peak with an onset of approximately 100 oC and peak temperature 123oC can be clearly seen followed 
by a sharp melting point at 152 oC. According to the literature data, this melting belongs to 
paracetamol form II (Shadiand and Iba'a, 2011). This indicates the high instability of PF 2:1 even 
under mild storage condition. The existence of the exothermic transition, which is likely to be the 
recrystallization of the material, indicates that the heating of the DSC run accelerated the 
crystallization. Although no clear melting can be seen in the DSC results of the aged PF 1:1 samples, a 
weak endothermic transition (likely to be a melting) with an onset of 110 oC can be identified. The 
aged PF 1:2 samples showed no melting in the DSC results suggesting being the most stable 
amorphous sample. However a weak Tg like transition at around 50 C is observed for PF 1:2 after 7 
days aging. If this is a true Tg, it indicates the phase separation of some proportions of phase separated 
amorphous felodipine. The above results indicate thatthe physical stability of the three systems after 7 
days aging is in the order of P:F 1:2> 1:1>2:1. Figure 4.1b shows the physical stability studies of PF 
co-amorphous system under 0% RH/room temperature after 14 days aging. Similar to the 7 days aging 
data, clear Tgs were detected for all samples. The PF 2:1 shows similar results as the physical stability 
of 7 days aging, a broad recrystallization followed by a melting peak at 152 oC can be observed. For 
the aged PF 1:1a clear but broad melting point at 116 oC can be seen which indicates the clear 
instability of PF 1:1 after 14 days aging. The DSC results of the aged PF 1:2 show a sharp melting 
point at 113 oC indicating the instability after 14 days aging. The low melting compounds observed in 
the DSC results of 14 days aged P:F 1:1 and 1:2 could be the same origin. However this low melting 
does not match any melting point of the polymorphic forms of either paracetamol or felodipine, 
indicating the possibility of the formation of co-crystals. This new species was also observed in the 
co-amorphous system stored under 75% RH/40 C. Its origin was later further investigated by PXRD 
and ATR-FTIR in section 4.3.2. It is also interesting to note that the weak Tg around 50 C again is 
observed for both PF 1:2 and 2:1 after 14 days aging. As discussed above, if this is a true Tg, this could 
be the evidence of the phase separation of amorphous felodipine from the co-amorphous mixture.  
 
Overall, under 0% RH/RT, the P:F 1:1 and 1:2 demonstrated similar behaviour and the 
recrystallization of a small quantity of a new species was observed. However, P:F 2:1 exhibited 
different physical stability in comparison to 1:1 and 1:2. The high tendency of paracetamol form II 
recrystallization was clearly demonstrated indicating the supersaturation of paracetamol in the 
co-amorphous system.  
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Figure 4.1 DSC results of P-F co-amorphous 1:1, 1:2 and 2:1 aged under 0% RH/RT for 7 days 
(a) and 14 days (b) 
 
4.3.1.2 ATR-FTIR 
As the Figure 4.2, no crystalline NH peaks of paracetamol and felodipine can be seen in the IR spectra 
of the aged PF 1:1 and 1:2 systems after 1, 3, 7 and 14 days. For carbonyl groups, a peak at 1661cm-1, 
this peak is same as carbonyl group of fresh sample, indicating the PF 1:1 co-amorphous system is 
stable within 14 days under 0%RH/RT. The detected small amount of the crystalline material with a 
melting of 113 C is not evident in the ATR-FTIR results. This is likely to be due to the poorer limit of 
detection of IR of crystalline materials than DSC. A good physical stability was observed in PF 2:1 
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system under the same condition for only up to 3 days. After 3 days aging, the O-H regions of the 
samples show significant alternation indicating the crystallisation of paracetamol. 
 
According to ATR-FTIR results, both PF 1:1 and 1:2 systems show good physical stability under 0% 
RH/RT. As there is no clear hydrogen bonding between paracetamol and felodipine was identified via 
IR as discussed in Chapter 3, the mechanism of stabilisation is likely to be associated with the 0% RH 
which eliminate the plasticisation effect of moisture sorption for the samples as well as the increased 
overall Tg than the Tg of amorphous paracetamol. The poor physical stability of the PF 2:1 system is 
mainly associated with the recrystallization of paracetamol form II. This indicates that the system is 
likely to have gone through amorphous phase separation of the amorphous paracetamol and 
amorphous felodipine. Because of the higher content and poorer stability of amorphous paracetamol, 
recrystallisation of paracetamol was detected as a result of this phase separation. This phase separation 
was evidenced by the Tg-like transition observed in the DSC results.  
 
Figure 4.2 ATR-FTIR results of P-F co-amorphous 1:1, 1:2 and 2:1 aged under 0%RH/RT after 
1, 3, 7 and 14 days 
 
4.3.2 Physical stability of PF co-amorphous systems under 75%RH/40 oC 
4.3.2.1 DSC 
For PF 1:1 co-amorphous system, it can be clearly observed that the samples shows melting points 
after 1, 3, 7 and 14 days at a range of temperatures 126, 134, 145 and 158 oC indicating they are 
different species of crystalline material. The identifications of the crystalline materials based on the 
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DSC results are difficult as both paracetamol and felodipine have polymorphic forms with melting 
points similar to these temperatures. Therefore in the following sections, PXRD and ATR-FTIR were 
used to further characterise them. The fact that no clear presence of exothermic recrystallization peak 
indicating these crystalline materials were not generated through the DSC heating which is different 
from the fresh PF 2:1 samples. For PF 1:2 co-amorphous system after 1 days, it shows a small melting 
peaks at approximately 120 and 125 °C. After 3 and 7 days aging a melting point at 109 oC can be 
seen. There is a melting point at 120 °C after 14 days aging of the PF 1:2 co-amorphous system. For 
the PF 2:1 system, after 1, 3, 7 and 14 days aging similar results were obtained. A melting point 
between 148-151 oC was observed. As this system contained more paracetamol, this is likely to be the 
melting of paracetamol form II.  
 
If judging by the amount of recrystallized materials, the PF 1:2 co-amorphous system is the most 
stable system under related humidity 75%RH/40 oC with the least amount of crystalline melting 
enthalpy. Although the PF 1:2 system was in the progressing of recrystallization, the speed of 
recrystallization was slower than the other systems. This may be attributed to the higher overall Tg of 
PF 1:2 system is higher than the other systems (Tg of PF 1:2 is 41.5 oC). However overall none of the 
systems are stable under this stressed condition. 
 
It is worth mentioning that there are low melting transitions between 110-120 °C were observed in 
aged PF 1:2 system. This low melting does not match any melting of polymorphic forms of 
paracetamol and felodipine. Therefore there is a possibility of the crystallisation of 
paracetamol-felodipine co-crystals. However due to the time constrain, the formation of co-crystal was 
not investigated further.  
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Figure 4.3 DSC results of P-F co-amorphous 1:1 (a), 1:2 (b) and 2:1 (c) under 75%RH/40 °C 
after 1, 3, 7 and 14 days 
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4.3.2.2 PXRD 
PXRD results of the physical stability of PF co-amorphous systems aged under 75%RH/40 oC are 
summarised in Table4.1. Despite DSC detected the presence of small amount of crystalline materials, 
PXRD still ‘recognised’ the PF 1:2 system being fully amorphous. Again this may be associated with 
the difference in the limit of detection of different characterisation techniques. The PF 1:1 
co-amorphous system showed amorphous features up to 3 days. Significant crystalline peak were seen 
after 7 days, indicating the samples started recrystallizing after 7 days. The PF 2:1 showed 
recrystallization after 1 days again. The order of the physical stability of the co-amorphous system 
agrees well with the DSC results.  
 
PXRD was further used to identify the recrystallized materials. By comparing the crystalline 
paracetamol and felodipine PXRD peak with the crystalline peaks of in the diffraction patterns of PF 
1:1 and 2:1 (Figure 4.4 and 4.5), it can be clearly observed that most of the diffraction peaks in the 
diffraction pattern of aged PF 2:1 belong to crystalline paracetamol. Moreover, in both cases as the 
recrystallization progresses, more paracetamol diffraction peaks were detected with increased 
intensities.  
 
Table 4.1 PXRD data of P-F co-amorphous system 1:1, 1:2 and 2:1 fresh, aged under 75% RH/ 
40 C for 1, 3, 7 and 14 days 
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Figure 4.4 PXRD results of P-F co-amorphous system 1:1 aged under 75% RH/40 C for 7 and 
14 days 
 
 
 
 
Figure 4.5 PXRD results of P-F co-amorphous system 2:1 aged under 75% RH/40 C for1, 3 and 
7 days 
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Figure 4.6 PXRD results of P-F co-amorphous system 1:2aged under 75% RH/40 C for1, 3, 7 
and 14 days 
 
4.3.2.3 ATR-FTIR  
The higher physical stability of PF 1:1 co-amorphous system and 1:2 co-amorphous systems under 
75%RH/40  oC also was investigated by ATR-FTIR. The results are shown in Figure 4.6 and 4.7. For 
PF 1:1 co-amorphous system no characteristic crystalline paracetamol and felodipine IR peak was 
observed after 1 and 3 days aging. For PF 1:1 co-amorphous system after 7 days and 14 days (data not 
shown due to the data lose in the lab fire in July 2017) revealed a NH peak at 3322 cm-1, which is 
typical of crystalline paracetamol, confirming the presence of crystalline paracetamol in this PF 1:1 
system. In addition, the shape of NH peak for PF 1:1 system is very clear and sharp, indicating no 
crystalline felodipine coexistent in this system. For carbonyl peaks of the PF 1:1 system, it is evident 
that the C=O peak of PF 1:1 system at 1608 cm-1which agrees well with the C=O peak of crystalline 
paracetamol. Other evidences of the presence of crystalline paracetamol in the aged PF 1:1 include the 
peak at 833cm-1which aligns with the peak at 833cm-1of crystalline paracetamol. For aged PF 2:1 
system, crystalline paracetamol was detected by the crystalline NH peak at 3321 cm-1. No crystalline 
paracetamol and felodipine N-H and C=O peaks were detected by ATR-FTIR for PF 1:2 
co-amorphous system. Overall, the ATR-FTIR results of PF 1:1, 1:2 and 2:1 systems are in good 
agreement with PXRD results, but show lower detection sensitive of crystalline content in the aged 
samples than DSC. The high level stress humidity and temperature significantly accelerated the 
recrystallization process of the co-amorphous systems. The PF 2:1 showed poorest stability followed 
by PF1:1 and PF 1:2 co-amorphous systems is most stable in comparison to PF 1:1 and 2:1 systems. 
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Figure 4.7 ATR-FTIR spectra of P-F 1:1 co-amorphous system fresh, aged for 1, 3 and 7 days 
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Figure 4.8 ATR-FTIR spectra of P-F co-amorphous system 1:2 and 2:1 fresh, aged for 1, 3 and 7 
days 
 
(*Note: 14 days data lose in the IR machine which was in a lab fire in July 2017) 
 
4.4 Conclusion 
In this chapter, physical stability studies under different aging conditions of co-amorphous materials 
were investigated. It is very clear that the high related humidity and temperature (75%RH/40oC) had 
significant effect on the stability of co-amorphous materials. By comparing the results of physical 
studies between different ratio of co-amorphous material, the co-amorphous PF 1:2 showed better 
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physical stability under 75%RH/40C and 0%RH/room temperature than PF 1:1. The co-amorphous PF 
2:1 showed least physical stability. However, as all three systems showed some recrystallization after 
14 days, stabilisation of the co-amorphous is needed. Therefore, Chapter 5 investigated the 
stabilisation effect of polymeric additives for the co-amorphous systems.  
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Chapter 5 Stabilisation of co-amorphous systems by polymeric 
solid dispersion  
 
5.1 Introduction 
As discussed in the previous Chapter, the co-amorphous systems exhibited high physical instability 
under 75%RH/40 °C storage condition. Amorphous polymer based solid dispersions have been widely 
reported to be able to stabilize amorphous drugs (Qiang et al., 2016). Solid dispersions can be 
prepared using a wide range of processing methods. In this study, HME was used to prepare the solid 
dispersion samples containing the co-amorphous systems. HME was selected for its effectiveness in 
fabricating uniformly dispersed polymeric glass solutions (Laitinen et al., 2013). HME has also been 
already widely adopted by pharmaceutical industry, thus it is processing method that is easy to 
scale-up.  
 
In Chapter 4, the significant amount of the low melting new species was detected by DSC in the aged 
PF 1:1 samples which was speculated as possible co-crystals of paracetamol and felodipine). 
 
The aim of this Chapter is evaluate the stabilization capability of solid dispersion of the co-amorphous 
systems. PF 1:1 co-amorphous system was selected as the model system for the investigation due to its 
strong evidence of forming interactive complexes between felodipine and paracetamol in the 1:1 
system. 
 
5.2 Methods 
5.2.1 Preparation of solid dispersion by HME 
Physical mixtures of paracetamol, felodipine and Soluplus with different ratios including 1:3 
(paracetamol:Soluplus PS and felodipine:Soluplus FS), 1:7 (paracetamol:Soluplus PS and 
felodipine:Soluplus FS), 1:1:2 (paracetamol:felodipine:Sopluplus PFS) and 1:1:6 
(paracetamol:felodipine:Soluplus PFS) were blended prior to HME (Table 5.1). The physical mixtures 
were fed into a co-rotating twin-screw extruder (HAAKE MiniLab II Micro Com-pounder, Thermo 
Electron, Karlsruhe, Germany) that was operated at an extrusion temperature of 140 °C and a screw 
speed of 100 rpm. The extrudates were collected as uniform rods.   
 Table 5.1 Formulation of the HME solid dispersions 
Formulation Ratio 1 (w/w) Ratio 2 (w/w) 
Paracetamol –Soluplus (P-S) 1:3 1:7 
Felodipine –Soluplus (F-S) 1:3 1:7 
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5.2.2 Storage condition 
The extrudates were stored at75% RH/RT, 75% RH/40 °C and 0%RH/room temperature for up to 4 
weeks for stability studies.  
 
5.2.3 Solid-state characterisation 
SEM, DSC, PXRD, and ATR-FTIR were used to monitor the physical stability of the solid dispersions 
containing either single amorphous drug or the co-amorphous systems. 
 
5.2.4 In-vitro drug release studies 
Dissolution testing was carried out in dissolution testing apparatus (Caleva8ST, Germany) using BP 
apparatus II paddle method. All tests were performed using a paddle rotation speed of100 rpm in 900 
mL 0.1M HCl (pH 1.2) at 37 °C. The extrudates loaded with equivalent to 10mg of felodipine and 
paracetamol was used for individual dissolution test. The dissolution samples withdrawn at each time 
point were filtered through 0.22µm filtration membrane before UV testing. The samples were 
measured using a UV–VIS spectrophotometer (Perkin-Elmer Lambda 35, USA) at 363 nm and 257nm 
for felodipine and paracetamol, respectively. 
 
5.3 Results and discussion  
5.3.1 Morphologies of the extrudates 
As seen in Figure 5.1, all freshly prepared HME extrudates are visually transparent indicating no 
significant amount of crystalline drug present in the solid dispersions. Figure 5.2 shows the SEM 
images of the surfaces of the freshly prepared solid dispersions. Again no crystalline drug particle was 
detected by SEM indicating the amorphous nature of all of solid dispersions.  
 
Paracetamol – felodipine – Soluplus (P-F-S) 1:1:2 1:1:6 
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Figure 5.1 Visual appearances of the freshly prepared HME extrudates of (a)P-S1:3; (b)P-S1:7; 
(c)F-S1:3; (d) F-S1:7; (e)P-F-S1:1:2; (f)P-F-S1:1:6 
 
 
Figure 5.2 SEM images of the freshly prepared extrudates of (a) P-S 1:3; (b) P-S 1:7; (c) F-S 1:3; 
(d) F-S 1:7; (e) P-F-S 1:1:2; (f) P-F-S 1:1:6 
 
The SEM results of the solid dispersions aged under most stressed condition (75% RH/40 C) for 4 
weeks are shown in Figure 5.3. Few small crystalline particles can be seen in the binary solid 
dispersions. However the solid dispersions containing co-amorphous systems show no sign of drug 
crystals at both surfaces and cross-sections. The SEM images of the samples aged under the other two 
conditions (75% RH/ RT and 0% RH/RT) showed no crystallisation in any samples (data not shown).  
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Figure 5.3 SEM images of the solid dispersion samples aged at 75%RH/40 °C for 4 weeks (a) P-S 
1:3; (b) P-S 1:7; (c)F-S 1:3; (d)F-S 1:7; (e)P-F-S 1:1:2; (f) P-F-S 1:1:6;(g) cross section of P-F-S 
1:1:2; (h)cross section of P-F-S 1:1:6 
 
However after aging, the most significant physical form changes were observed in P-F-S 1:1:2 aged 
under the condition of relative humidity of 75%/40C. As seen in Figure 5.4, the extrudates were 
completely deformed and liquidified due to the high aging temperature and relative humidity. 
Therefore significant moisture uptake was suspected which could be responsible for the deformation. 
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This is confirmed by the TGA results showed in Figure 5.4, in which approximately 1.2% weight loss 
(which is likely to moisture) was detected with heating up to 100C. The continuous weight loss above 
100C is an indication of chemical degradation and thermal decomposition of the samples.  
 
Figure 5.4 The liquification of P-F-S 1:1:2extrudates after 4 weeks aging at 75%RH/40 °C and 
the TGA result of the sample 
 
5.3.2 Thermal behavior of the extrudates 
Figure 5.5 shows the DSC results of the freshly prepared binary and co-amorphous solid dispersions. 
As seen in Figure 5.5 there is no clear melting of crystalline drug can be detected indicating the full 
amorphous nature of all the solid dispersions. Single Tg was detected for all freshly prepared 
dispersions suggesting no clear amorphous phase separation in these systems. With increasing the 
Soluplus content, the Tg of the dispersions increases. The DSC measured Tg values of the fresh 
samples are compared with predicted Tg calculated using Fox equation. As seen in Table 5.2, for all of 
solid dispersion systems, the Tgs of formulations are lower than the calculated Tgs. According 
to the literature, this indicates that the drug-polymer interactions are weaker than the 
molecular interactions between two drug molecules (Shamblin et al.,1998). 
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Figure 5.5 DSC results of the freshly prepared solid dispersions 
 
 
 
Afte
r 
agin
g 
for 4 weeks under 0%RH/RT (Figure 5.6), the DSC results of the solid dispersions show reductions of 
the Tg of all samples between 5-10 C. However, no melting was detected. Normally decreases of the 
Tg values should be an indication of either increased amount of amorphous content or plasticisation 
effect. The increase in amorphous content is not possible. In this case, as the aging condition was 0% 
RH, it is unlikely that the observed decreases in Tg is due to the moisture absorption. However, 
moisture uptake during the DSC samples preparation is possible. For the samples aged for 4 weeks 
under 75% RH/40 C (Figure 5.7), significant moisture losses as broad endothermic peaks are detected 
for all samples. No clear melting peaks were detected in any of the aged samples. Amorphous phase 
separation is evidenced by the presences of double Tg in F-S 1:3 and P-F-S 1:1:2. Clear Soluplus Tg 
was detected in both samples indicating the phase separation of amorphous dispersions and the 
polymer. Overall the DSC results indicated good physical stability of most of the samples except the 
F-S 1:3 and P-F-S 1:1:2 systems, which show some signs of amorphous, phase separation. No drug 
recrystallization was detected in any aged samples. 
Table 5.2 Comparison of Tg values of P-S 1:3, P-S 1:7, F-S 1:3, F-S 1:7,P-F-S 1:1:2 and P-F-S 
1:1:6 measured experimentally by DSC and predicted by Fox equation 
Formulation P-S 1:3 P-S1:7 F-S 1:3 F-S1:7 P-F-S 
1:1:2 
P-F-S 
1:1:6 
Experimental 
Tg (C) 
46.6 51.1 52.2 55.1 46.1 49.4 
Predicted Tg 
(C) 
47.4 56.8 59.2 62.5 48.8 54.2 
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Figure 5.6 DSC results of the 4-weeks aged solid dispersions at 0%RH/RT 
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Figure 5.7 DSC results of the 4-weeks aged solid dispersions at 75%RH/40 °C 
 
 
5.3.3 PXRD  
The freshly prepared solid dispersions are all PXRD amorphous as seen in Figure 5.8. Similar to the 
conclusion drawn from the DSC results, no crystalline peaks were detected in any of the aged samples 
(Figure 5.9 and 10) indicating the good physical stability of all solid dispersions.   
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Figure 5.8 PXRD diffraction patterns of freshly prepared solid dispersions 
 
Figure 5.9 PXRD of the 4-week aged solid dispersions at 0% RH/RT 
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Figure 5.10 PXRD diffraction patterns of 4-week aged solid dispersions at 75% RH/40 C 
 
5.3.4 ATR-FTIR 
The ATR-FTIR spectra of the freshly prepared solid dispersions again demonstrate the full amorphous 
nature (Figure 5.11). Some peak shifts of the CO of paracetamol and felodipine in the spectra of the 
binary dispersions indicate molecular interaction (hydrogen bonding) between paracetamol, felodipine 
and the polymer, which contributed to the stabilisation of the dispersions. It is very hard to analyse the 
spectra of the carbonyl region of paracetamol between 1800 and 1500 cm−1 because of peak 
overlapping with the carbonyl peaks of Soluplus. Therefore, the NH peaks at 3369 cm-1 and 3327 cm–1, 
which are the signature crystalline felodipine and paracetamol peaks, respectively, were used to 
identify any drug recrystallisation in the aged samples. No crystalline felodipine paracetamol NH 
peaks were observed for the extrudates aged under all conditions (Figure 5.12 and 13). This indicates 
the solid dispersions were still in their amorphous states after aging. The samples aged for 4 weeks 
(data not shown because the data was in the PC damaged by the lab fire) showed no significant 
difference in ATR-FTIR spectra. 
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Figure 5.11 ATR-FTIR spectra of crystalline paracetamol, felodipine and freshly prepared 
P-F-S extrudates with 1:1:2 and 1:1:6 ratios (a) 4000-2000 cm-1 region (b) 1950-1500 cm-1 region 
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Figure 5.12 ATR-FTIR spectra of P-S extrudates with (a) 1:3 and (b) 1:7 ratios aged for 2 weeks 
at 75%RH/RT, 0%RH/RT and 75%RH/40 C 
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Figure 5.13 ATR-FTIR spectra of P-F-S extrudates (a) with 1:1:2 and (b) 1:1:6 ratios aged for 2 
weeks at 75%RH/RT, 0%RH/RT and 75%RH/40 C 
 
5.3.5 In vitro drug release 
The dissolution profiles of the freshly prepared PFS 1:1:6 and 1:1:2 dispersions in the form as 
cylindrical shaped extrudate rods (not as traditional power form) are shown in Figure 5.14. For both 
formulations, felodipine had less than 2% dissolution. This is likely to be due to the slow dissolution 
of Soluplus as a cylinder rod which facilitated the crystallisation of felodipine in the extrudates and 
significantly hindered the dissolution of felodipine. Paracetamol in the PFS 1:1:6 shows good release 
profile which matches the release behaviour of the paracetamol alone. But only 6% of paracetamol 
dissolved from the PFS 1:1:2 solid dispersion. This may be attributed to the recrystallisation of 
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felodipine in the polymeric matrices which increased the hydrophobicity of the samples and reduced 
water penetration in the samples and the subsequent dissolution of paracetamol.  
 
Figure 5.14 The in vitro drug release profiles of freshly prepared P-F-S 1:1:2 and 1:1:6 
extrudates 
 
After aged 4 weeks, the dissolution profiles of paracetamol in PFS 1:1:6 show significant decreases in 
the dissolution rate (Figure 5.15). In fact a nearly linear zero order release profile cane be seen in all 
aged PFS 1:1:6 samples. As the extrudates maintained the cylindrical shape throughout the dissolution 
test, this indicates the diffusion controlled release behaviour in aged PFS 1:1:6 samples. Different 
storage conditions show little impact on the paracetamol release behaviour in the aged samples. 
However for the aged PFS 1:1:2 samples, low paracetamol releases were observed (Figure 5.16). 
Similar to the fresh samples, the recrystallisation of felodipine in the extrudates during the dissolution 
test could be the main reason of the low paracetamol release. The releases of felodipine from the aged 
P-F-S extrudates were all less than 1.5% over the 8-hour dissolution tests. Therefore the data is not 
included in the Figures. 
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Figure 5.15 The in vitro drug release profiles of paracetamol from aged (4 weeks) P-F-S 1:1:6 
extrudates 
 
Figure 5.16 The in vitro drug release profiles of paracetamol from aged (4 weeks) P-F-S1:1:2 
extrudates 
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5.4 Conclusion 
This Chapter investigated the physical stability of solid dispersions of the co-amorphous systems 
incorporated into Soluplus matrices. From all the solid-state characterisation data, it is clear that the 
physical stability of the co-amorphous systems were improved. However, the in vitro dissolution data 
showed that with high co-amorphous content hindered the release of both drugs. Aging even had 
significant impact on slowing the release of paracetamol from the co-amorphous solid dispersions. 
However, it should be highlighted that the dissolution in this study were performed using extrudates as 
strands instead of power form, which could be useful for controlled release formulation applications. 
The results of this Chapter have highlighted the importance of effect of polymer additives on the 
dissolution enhancement of the co-amorphous systems.   
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Chapter 6 Conclusion remarks and future work 
 
6.1 Physical stabilities for co-amorphous systems  
In this project, co-amorphous paracetamol-felodipine (P-F) was selected as the model system based on 
the prediction of potential intermolecular interaction (mainly hydrogen bonding potentials) between 
the two drugs. The amorphous paracetamol has poor physical stability due to high molecular mobility 
at room temperature and the low Tg. Crystalline felodipine has poor aqueous solubility, therefore the 
conversion to its amorphous state was expected to improve the dissolution rate of felodipine and 
subsequently bioavailability. Therefore the rationale behind forming the co-amorphous system of P-F 
is to improve the physical stability of amorphous paracetamol and the dissolution rate of crystalline 
felodipine.  
 
All of sample were stored under 0% RH/ room temperature and 75% RH/40 °C for up to 14 days. 
Under such conditions, amorphous paracetamol alone would recrystallize within 2 hours (Piera et al., 
2000). Amorphous felodipine has been reported to show recrystallization within 1 day under such 
conditions (Umesh et al., 2013). As discuss in Chapter 4, the co-amorphous P-F 1:2 shows better 
physical stability (without recrystallization) than P-F1:1 under accelerated stress condition. For P-F 
1:1, the sample were stable up to 7 days under 75 RH%/40C, whereas P-F 1:2 were stable for up to 14 
days. Both of formulations can be stable up to 14 days under0% RH/room temperature. Co-amorphous 
P-F 2:1 showed the poorest physical stability with crystallization of paracetamol observed within 1 
day after aging. For both 1:1 and 1:2 systems, the stability was improved compared to amorphous 
paracetamol and amorphous felodipine alone. Despite the overall Tg values of the co-amorphous 
systems are still relatively low (approximately 35-40 °C), the results indicate that the formation of 
co-amorphous systems has the ability of reduce the crystallization tendency of the two amorphous 
drugs in comparison to their own amorphous state. This may be attributed to the intermolecular 
interactions between the two species. The high recrystallization tendency of P-F 2:1 system is likely to 
be attributed to the stronger intramolecular interaction of paracetamol molecules than intermolecular 
interactions between paracetamol and felodipine. This led to the rapid nucleation and crystallization of 
the amorphous content of paracetamol in the system. 
 
In terms of the improvement of the dissolution rate, felodipine showed no significant improvement for 
the dissolution from the co-amorphous systems. Supersaturation and crystallization in the dissolution 
media were observed rapidly after the initiation of the dissolution test. This indicates that the 
co-amorphous system was not able to sustain a high level of supersaturation of felodipine. This may 
be due to the lack of nucleation inhibitors in the systems in comparison to other polymer based solid 
dispersions in which often polymers act as the nucleation inhibitor after dissolution. The dissolution 
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rate of paracetamol from the co-amorphous system is also hindered in comparison to eh amorphous 
paracetamol alone. The intermolecular interaction between paracetamol and felodipine may play a role 
in delaying the dissolution of paracetamol, in particular if the paracetamol molecules are trapped in the 
recrystallized felodipine crystals.  
 
Overall, based on the behaviour of the co-amorphous systems, we have achieved the goal of 
improving the physical stability of the amorphous drugs, but not accomplished the aim of improving 
the dissolution rate of the two drugs. Therefore, to further enhance the stability and the dissolution rate 
of the drugs, polymer excipients were added to act as the stabilizer and nucleation inhibitor during 
dissolution. P-F 1:1co-amorphous systems were selected as the model systems to be further 
investigated due to their intermediate stability and in vitro dissolution results (as well as the time limit 
of the project).  
 
6.2 Comparison of physical stability between co-amorphous and solid dispersions 
Soluplus was selected as the model polymeric excipient for the preparation of the amorphous 
dispersions. This choice was made based on the good stabilizing capability of Soluplus for each 
individual amorphous drug (Chapter 5). After the incorporation of the co-amorphous systems into the 
solid dispersions via hot melt extrusion, the physical stabilities of the drugs were improved in 
comparison to the co-amorphous systems. All of sample stored under 75% RH/RT, 0% RH/ RT and 
75% RH/40C for solid dispersion with aging up to 3 months. Under the stressed condition, the 
amorphous drugs were stable in the dispersions for at least 1 month. The crystallization paracetamol 
was still observed for longer aged samples indicating that intrinsic high molecular mobility of 
amorphous paracetamol is still difficult to overcome. However, the amount of recrystallization is 
small, thus DSC and PXRD results showed little evidence of significant crystallization. This stability 
enhancement can be attributed to the presence of Soluplus which anti-plasticize the two low Tg 
amorphous drug (DSC results confirmed) and drug-polymer interactions (ATR-FTIR results 
confirmed).  
 
In terms of the dissolution rate enhancement, the incorporation into the Soluplus based solid 
dispersions showed significantly faster release of paracetamol from the extrudates than power form 
co-amorphous systems. Taking into account that the physical form difference (extrudate as matrix 
system and power form co-amorphous which has much higher surface area-to-volume ratio), this 
indicates that the presence of Soluplus significantly improve the dissolution of paracetamol. This 
could be explained by the dispersion of paracetamol molecules within the soluble polymer matrix 
instead of being trapped in the recrystallized felodipine solids (as illustrated in Figure 6.1).  
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Figure 6.1 Molecular illustrations of the differences of co-amorphous and solid dispersion 
stabilized co-amorphous systems 
 
6.3 Recommended future work 
This project has accumulated promising results towards the understanding of co-amorphous systems 
which would be useful for future drug delivery applications such as polypill formulation development 
(when multiple drugs are being delivered in a single dose unit). However, due to the time constrain of 
the project there are still many aspects of in depth investigations of the subject needed. These include 
the thermodynamic properties of the co-amorphous systems such as molecular relaxation behaviour, 
the molecular interactions and their role in stabilizing both amorphous drugs, and the effect of 
polymeric additives on the stability and dissolution behaviour of the co-amorphous materials. 
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